• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.

作者信息

England James T, McNamara Caroline J, Kennedy James A, Capo-Chichi Jose-Mario, Huang Jingyue, Arruda Andrea, Nye Taylor, Cheung Verna, Claudio Jaime O, Maze Dawn, Sibai Hassan, Tierens Anne, Tsui Hubert, Bankar Aniket, Xu Wei, Stockley Tracy, Gupta Vikas

机构信息

Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

出版信息

Leukemia. 2022 Jun;36(6):1689-1692. doi: 10.1038/s41375-022-01544-x. Epub 2022 Mar 26.

DOI:10.1038/s41375-022-01544-x
PMID:35347238
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9162913/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9770/9162913/a264ca453ede/41375_2022_1544_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9770/9162913/7a3028b5f29e/41375_2022_1544_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9770/9162913/a264ca453ede/41375_2022_1544_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9770/9162913/7a3028b5f29e/41375_2022_1544_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9770/9162913/a264ca453ede/41375_2022_1544_Fig2_HTML.jpg

相似文献

1
Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.骨髓纤维化中JAK抑制剂治疗失败的临床和分子相关性：来自分子注释队列的长期数据
Leukemia. 2022 Jun;36(6):1689-1692. doi: 10.1038/s41375-022-01544-x. Epub 2022 Mar 26.
2
Comparison of clinical outcomes between transplant and nontransplant therapies in myelofibrosis following failure of first-line JAK-inhibitor.
Am J Hematol. 2023 May;98(5):E127-E129. doi: 10.1002/ajh.26890. Epub 2023 Mar 7.
3
New drugs in myelofibrosis: Critical assessment of additional value to monotherapy with JAK inhibitors.骨髓纤维化中的新药：对 JAK 抑制剂单药治疗附加价值的批判性评估。
Am J Hematol. 2024 May;99(5):978-981. doi: 10.1002/ajh.27248. Epub 2024 Feb 8.
4
Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?Janus 激酶抑制及其对骨髓纤维化治疗格局的影响：从缓解到治愈？
Br J Haematol. 2012 May;157(4):426-37. doi: 10.1111/j.1365-2141.2012.09108.x. Epub 2012 Mar 29.
5
Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.生活质量可独立预测骨髓纤维化的总生存期：口服Janus激酶抑制剂治疗的骨髓纤维化对照研究（COMFORT-I）的关键见解
Br J Haematol. 2022 Sep;198(6):1065-1068. doi: 10.1111/bjh.18329. Epub 2022 Jun 24.
6
Momelotinib for the treatment of myelofibrosis with anemia.莫雷洛替尼治疗伴贫血的骨髓纤维化。
Future Oncol. 2022 Jun;18(20):2559-2571. doi: 10.2217/fon-2022-0276. Epub 2022 May 23.
7
Cytopenic myelofibrosis: prevalence, relevance, and treatment.细胞减少性骨髓纤维化：患病率、相关性和治疗。
Expert Opin Pharmacother. 2023 Jun;24(8):901-912. doi: 10.1080/14656566.2023.2203318. Epub 2023 Apr 17.
8
FDA approves fourth JAK inhibitor for myelofibrosis.美国食品药品监督管理局批准第四种用于治疗骨髓纤维化的JAK抑制剂。
Nat Rev Drug Discov. 2023 Nov;22(11):862. doi: 10.1038/d41573-023-00163-0.
9
Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.芦可替尼治疗原发性骨髓纤维化所致持续性足部溃疡
J Oncol Pharm Pract. 2018 Apr;24(3):226-228. doi: 10.1177/1078155217697488. Epub 2017 Mar 10.
10
Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations.骨髓纤维化中 JAK2 抑制剂的跨研究比较：风险和建议。
Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):714-718. doi: 10.1016/j.clml.2023.06.004. Epub 2023 Jun 9.

引用本文的文献

1
Molecular profiling in MPN: who should have it and why?骨髓增殖性肿瘤的分子特征分析：谁应该进行以及为何要进行？
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):524-534. doi: 10.1182/hematology.2024000576.
2
Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.加拿大 MPN 小组研究：加拿大青少年和年轻成年人骨髓增殖性肿瘤的临床特征和长期预后。
Leukemia. 2024 Mar;38(3):570-578. doi: 10.1038/s41375-024-02155-4. Epub 2024 Feb 6.
3
Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling.
探索骨髓纤维化的分子格局，重点关注Ras和丝裂原活化蛋白（MAP）激酶信号传导。
Cancers (Basel). 2023 Sep 21;15(18):4654. doi: 10.3390/cancers15184654.